{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:59:01Z","timestamp":1789657141886,"version":"4.0.1"},"reference-count":8,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,16]]},"DOI":"10.1182\/blood-2012-06-433821","type":"journal-article","created":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T16:41:29Z","timestamp":1345135289000},"page":"1529-1531","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":64,"title":["Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)\/PCM1-JAK2\u2013positive chronic eosinophilic leukemia"],"prefix":"10.1182","volume":"120","author":[{"given":"Els","family":"Lierman","sequence":"first","affiliation":[{"name":"Center for Human Genetics, KU Leuven\/University Hospital Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Selleslag","sequence":"additional","affiliation":[{"name":"AZ Sint-Jan, Brugge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Smits","sequence":"additional","affiliation":[{"name":"Center for Human Genetics, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Billiet","sequence":"additional","affiliation":[{"name":"AZ Sint-Jan, Brugge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vandenberghe","sequence":"additional","affiliation":[{"name":"Center for Human Genetics, KU Leuven\/University Hospital Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111808285203700_B1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14728222.2011.538683","article-title":"PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.","volume":"15","author":"Hoeller","year":"2011","journal-title":"Expert Opin Ther Targets"},{"issue":"7","key":"2019111808285203700_B2","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res"},{"issue":"5341","key":"2019111808285203700_B3","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","article-title":"A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science"},{"issue":"7","key":"2019111808285203700_B4","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V90.7.2535","article-title":"Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15:12) in a myeloid leukemia.","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood"},{"issue":"15","key":"2019111808285203700_B5","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2010-06-291310","article-title":"JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma.","volume":"117","author":"Van Roosbroeck","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2019111808285203700_B6","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111808285203700_B7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111808285203700_B8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/7\/1529\/1498649\/zh803312001529.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/7\/1529\/1498649\/zh803312001529.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:51:48Z","timestamp":1574085108000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/7\/1529\/30733\/Ruxolitinib-inhibits-transforming-JAK2-fusion"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,16]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,8,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-06-433821","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,16]]}}}